SMART Earnings Growth 30 ETF (SGRT)

On our desk, looking at SGRT's portfolio distribution, the heavy tilt toward Electronic Technology at over 47% of assets stands out immediately. When you combine that with top holdings like Dell, Western Digital, and Micron sitting right around 10% each, concentration risk is very real. Market sentiment is heavily tied to cyclical semiconductor and hardware demand cycles. If those specific segments miss earnings expectations, the fund's top-heavy nature will magnify the downside volatility, regardless of broader market conditions.

From a quantitative risk management perspective, SGRT operates as a non-diversified, actively-managed vehicle targeting large-cap U.S. equities with above-market growth potential. With a 59 basis point expense ratio and a portfolio where the top ten constituents make up roughly 70.68% of total assets, position sizing requires careful monitoring. Growth stocks inherently lack the downside dividend cushion found in value styles, leaving investors fully exposed to multiple contraction if forward-looking revenue projections falter.

In evaluating the fund's underlying architecture for our screening protocols, we note that SGRT targets U.S. domiciled large-cap companies with a weighted average market cap hovering around $356 billion. The inclusion of major health technology components like Eli Lilly at over 9% helps offset pure tech cyclicality, but the overall asset dispersion remains narrow with only around 23 total holdings. Analysts evaluating this ETF need to weigh the active selection strategy against its concentrated idiosyncratic risk profile.